⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17929302 | 1.00 | — | — | |
| SCHEMBL4630954 | 1.00 | — | — | |
| Hydrochloric Acid SCHEMBL10834143 | 0.98 | NOS2 (0.43) | — | |
| Hydrochloric Acid SCHEMBL10834147 | 0.98 | NOS2 (0.43) | — | |
| SCHEMBL15307927 | 0.93 | FDPS (0.43) | — | |
| SCHEMBL17929297 | 0.93 | FDPS (0.43) | — | |
| SCHEMBL4630547 | 0.93 | FDPS (0.43) | — | |
| SCHEMBL9040662 | 0.91 | FDPS (0.42) | — | |
| SCHEMBL9579255 | 0.82 | — | — | |
| SCHEMBL14296418 | 0.80 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20060182797-A1 | Sutained release formulation for venlafaxine hydrochloride | PHARMATHEN S.A. (GR) | 2006-08-17 | — | — | US | claimed |
| WO-2005009414-A1 | SUTAINED RELEASE FORMULATION FOR VENLAFAXINE HYDROCHLORIDE | PHARMATHEN S.A. (GR) | 2005-02-03 | — | — | WO | claimed |
| EP-1502587-A1 | Sustained release formulation for Venlafaxine hydrochloride | Pharmathen S.A. (GR) | 2005-02-02 | — | — | EP | claimed |
| US-20230295644-A1 | SURFACE EXPRESSION VECTOR USING TWO KINDS OF PROMOTERS DERIVED FROM LACTOBACILLUS CASEI FOR CONCURRENTLY EXPRESSING TWO TARGET PROTEINS AND METHOD FOR EXPRESSING PROTEINS ON MICROBIAL SURFACE BY USING SAME | BIOLEADERS CORPORATION (KR) | 2023-09-21 | — | — | US | disclosed |
| EP-3940077-A2 | SURFACE EXPRESSION VECTOR USING TWO KINDS OF PROMOTERS DERIVED FROM LACTOBACILLUS CASEI FOR CONCURRENTLY EXPRESSING TWO TARGET PROTEINS AND METHOD FOR EXPRESSING PROTEINS ON MICROBIAL SURFACE BY USING SAME | Bioleaders Corporation (KR) | 2022-01-19 | — | — | EP | disclosed |
| EP-3865578-A1 | SURFACE EXPRESSION VECTOR FOR CONSTITUTIVE HIGH-EXPRESSION USING PROMOTER OF GALACTOSE MUTAROTASE GENE DERIVED FROM LACTOBACILLUS CASEI, AND USE THEREOF | Bioleaders Corporation (KR) | 2021-08-18 | — | — | EP | disclosed |
| US-20110318384-A1 | VECTOR FOR TREATMENT VACCINE FOR STABLE AND CONSTITUTIVE HIGH-EXPRESSION CERVICAL CANCER AND RECOMBINANT LACTOBACILLUS TRANSFORMED BY THE SAME | BIOLEADERS CORPORATION (KR) | 2011-12-29 | — | — | US | disclosed |
| EP-2386645-A2 | VECTOR FOR TREATMENT VACCINE FOR STABLE AND CONSTITUTIVE HIGH-EXPRESSION CERVICAL CANCER AND RECOMBINANT LACTOBACILLUS TRANSFORMED BY THE SAME | Bioleaders Corporation (KR) | 2011-11-16 | — | — | EP | disclosed |
| US-8038688-B2 | Articulating suturing device and method | ABBOTT LABORATORIES (US) | 2011-10-18 | — | — | US | disclosed |
| US-20110171297-A1 | SUSTAINED RELEASE FORMULATION FOR VENLAFAXINE HYDROCHLORIDE | PHARMATHEN S.A. (GR) | 2011-07-14 | — | — | US | disclosed |
| EP-1502587-B1 | Sustained release formulation for Venlafaxine hydrochloride | PHARMATHEN SA (GR) | 2006-08-23 | — | — | EP | disclosed |
| US-20060182797-A1 | Sutained release formulation for venlafaxine hydrochloride | PHARMATHEN S.A. (GR) | 2006-08-17 | — | — | US | disclosed |
| WO-2005009414-A1 | SUTAINED RELEASE FORMULATION FOR VENLAFAXINE HYDROCHLORIDE | PHARMATHEN S.A. (GR) | 2005-02-03 | — | — | WO | disclosed |
| EP-1502587-A1 | Sustained release formulation for Venlafaxine hydrochloride | Pharmathen S.A. (GR) | 2005-02-02 | — | — | EP | disclosed |